In a PRL-secreting pituitary tumor cell line, the β-arrestin 2-biased DRD2 ligand UNC9994 induced a stronger reduction in cell proliferation compared to the unselective agonist cabergoline, the currently used drug for this type of tumor. The gene discussed is DRD2; the disease is neoplasm.